Isthmus Partners LLC Sells 7,005 Shares of Ingevity Corporation $NGVT

Isthmus Partners LLC decreased its holdings in Ingevity Corporation (NYSE:NGVT) by 9.7% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 65,240 shares of the company’s stock after selling 7,005 shares during the quarter. Isthmus Partners LLC’s holdings in Ingevity were worth $4,647,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. AQR Capital Management LLC boosted its holdings in shares of Ingevity by 10.9% during the 1st quarter. AQR Capital Management LLC now owns 13,410 shares of the company’s stock valued at $518,000 after acquiring an additional 1,323 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Ingevity by 5.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,790 shares of the company’s stock valued at $863,000 after purchasing an additional 1,080 shares during the last quarter. Empowered Funds LLC lifted its position in Ingevity by 12.9% during the first quarter. Empowered Funds LLC now owns 5,181 shares of the company’s stock valued at $205,000 after purchasing an additional 594 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Ingevity by 311.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company’s stock worth $23,769,000 after purchasing an additional 454,579 shares during the last quarter. Finally, Jane Street Group LLC boosted its holdings in Ingevity by 306.1% in the first quarter. Jane Street Group LLC now owns 88,883 shares of the company’s stock worth $3,519,000 after purchasing an additional 66,995 shares during the last quarter. Institutional investors own 91.59% of the company’s stock.

Insider Activity

In other news, SVP Terrance M. Dyer sold 496 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $68.49, for a total value of $33,971.04. Following the completion of the sale, the senior vice president directly owned 7,202 shares in the company, valued at $493,264.98. This represents a 6.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.88% of the stock is currently owned by insiders.

Ingevity Stock Performance

NGVT opened at $71.45 on Thursday. The company has a current ratio of 1.42, a quick ratio of 0.92 and a debt-to-equity ratio of 27.83. The company has a market cap of $2.48 billion, a price-to-earnings ratio of -20.13 and a beta of 1.16. The company’s 50 day moving average is $71.05 and its 200 day moving average is $69.49. Ingevity Corporation has a 12-month low of $39.74 and a 12-month high of $79.29.

Ingevity (NYSE:NGVT) last announced its earnings results on Wednesday, May 6th. The company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.31. Ingevity had a negative net margin of 10.55% and a positive return on equity of 207.82%. The business had revenue of $258.00 million during the quarter, compared to analysts’ expectations of $254.73 million. During the same period in the prior year, the company earned $1.01 earnings per share. The firm’s revenue was up 4.1% on a year-over-year basis. Ingevity has set its FY 2026 guidance at 4.700-5.200 EPS. On average, equities research analysts predict that Ingevity Corporation will post 5.05 EPS for the current year.

Analysts Set New Price Targets

NGVT has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ingevity in a research note on Tuesday, April 21st. Wall Street Zen raised Ingevity from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $80.00.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.